Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome

Neurochemistry International

Volumn 43, Issue 2, 2003, Pages 155-164

  Nisijima, Koichi ^a   Shioda, Katsutoshi ^a   Yoshino, Tatuki ^a   Takano, Kenji ^a   Kato, Satoshi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chlormethiazole; Diazepam; Hyperthermia; Hypothalamus; Microdialysis; Serotonin syndrome

Indexed keywords

5 HYDROXYTRYPTOPHAN; CLOMETHIAZOLE; CLORGYLINE; DIAZEPAM; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; RITANSERIN; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZOTEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ARTICLE; ATTENUATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG POTENCY; HYPERTHERMIA; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN BRAIN LEVEL; PREMEDICATION; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE; SEROTONIN BRAIN LEVEL; SEROTONIN SYNDROME; SURVIVAL TIME;

5-HYDROXYTRYPTOPHAN; ANIMALS; BODY TEMPERATURE; BRAIN; CHLORMETHIAZOLE; CLORGYLINE; DIAZEPAM; DISEASE MODELS, ANIMAL; FEVER; KINETICS; MALE; MICRODIALYSIS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; SEROTONIN SYNDROME; TIME FACTORS;

ANIMALIA;

EID: 0037410907     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(02)00213-9     Document Type: Article

References (32)

1. Bedford Russell A.R., Schwartz R.H., Dawling S. Accidental ingestion of "Ecstasy" (3,4-methylenedioxymethylamphetamine). Arch. Dis. Childhood. 67:1992;1114-1115.
2. Brubacher J.R., Hoffman R.S., Lurin M.J. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet. Hum. Toxicol. 38:1996;358-361.
3. Cross A.J., Jones J.A., Baldwin H.A., Green R. Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br. J. Pharmacol. 104:1991;406-411.
4. 2A receptors. Pharmacopsychiatry. 26:1993;53-58.
5. Davis J.M., Caroff S.N., Mann S.C. Treatment of neuroleptic malignant syndrome. Psychiatr. Ann. 30:2000;325-335.
6. 2A receptors in cerebral cortex. Neuropharmacology. 24:1985;947-952.
7. 2A receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology. 33:1994;411-421.
8. Dowden J., Reid C., Dooley P., Corbett D. Diazepam-induced neuroprotection: dissociating the effects of hypothermia following global ischemia. Brain Res. 829:1999;1-6.
9. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Case report. Pharmacopsychiatry. 39:1996;159-161.
10. Fisher A.A., Davis M.W. Serotonin syndrome caused by selective serotonin re-uptake inhibitors-metoclopramide interaction. Ann. Pharmacother. 36:2002;67-71.
11. Gasior M., Ungard J.T., Witkin J.M. Chlormethiazole: effectiveness against toxic effects of cocaine in mice. J. Pharmacol. Exp. Ther. 295:2000;153-161.
12. Gillman P.K. The serotonin syndrome and its treatment. J. Psychopharmacol. 13:1999;100-109.
13. 2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology. 38:1999;315-317.
14. Green A.R. 5-HT-mediated behavior animal studies. Neuropharmacology. 23:1984;1521-1528.
15. Hilton S.E., Maradit H., Moller H.J. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur. Arch. Psychiatr. Neurosci. 247:1997;113-119.
16. Keck P.E., Arnold L.M. The serotonin syndrome. Psychiatr. Ann. 30:2000;333-343.
17. Kline S.S., Mauro L.S., Scala Barnet D.M., Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin. Pharm. 8:1989;510-514.
18. Leysen J.E., Gommeren W., Van Gompel P., Wynants J., Janssen P.F.M., Laduron P.M. Receptor-binding properties in vitro and in vivo of ritanserin. Mol. Pharmacol. 27:1985;600-611.
19. Marley E., Wozniak K.M. Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J. Psychiat. Res. 18:1984a;173-189.
20. Marley E., Wozniak K.M. Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J. Psychiatr. Res. 18:1984b;191-203.
21. 2A receptors. Psychopharmacology. 117:1995;193-199.
22. Mills K.C. Serotonin syndrome. Critic. Care Clin. 13:1997;763-783.
23. Nisijima K., Yoshino T., Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome. Psychopharmacology. 150:2000;9-14.
24. 2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 890:2001;23-31.
25. Ögren S.O. Chlormethiazole: mode of action. Acta Psychiatr. Scand. 329(Suppl.):1986;13-27.
26. Pacák K., Palkovits M., Kvetñanský R., Yadid G., Kopin I.J., Goldstein D.S. Effects of various stressors on in vivo norepinephrine release in the hypothalamic paraventricular nucleus and on the pituitary-adrenocortical axis. Ann. NY Acad. Sci. 771:1995;115-130.
27. Paxinos, G., Watson, C., 1986. The rat brain in stereotaxic coordinates, 2nd ed. Academic Press, New York.
28. Schotte A., Janssen P.F.M., Gommere W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone comared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
29. Schwartz R.D., Yu X., Katzman M.R., Hayden-Hixson D.M., Perry J.M. Diazepam, given postischemia, protects selectively vulnerable neurons in the rat hippocampus and striatum. J. Neurosci. 15:1995;529-539.
30. Sternbach H. The serotonin syndrome. Am. J. Psychiatr. 148:1991;705-713.
31. Sydserff S.G., Cross A.J., West K.J., Green A.R. The effect of chlormethiazole on neuronal damage in a model of transient focal ischaemia. Br. J. Pharmacol. 114:1995;1631-1635.
32. A receptor sites in diazepam hypothermia. Gen. Pharmacol. 20:1989;855-859.